All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Safety and efficacy of teclistamab in patients with RRMM exposed to anti-BCMA: MajesTEC-1 Cohort C
Bookmark this article
|
Teclistamab, a B-cell maturation antigen (BCMA)-directed bispecific antibody therapy, was investigated and granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma (RRMM) as a result of the pivotal MajesTEC-1 (NCT04557098) trial. Results from Cohort C of MajesTEC-1 trial on safety and efficacy of teclistamab in patients with prior exposure to anti-BCMA therapies were published in Blood by Touzeau, et al.1 |
| Key learnings: |
|
An overall response rate (ORR) of 52.5% was observed, with 47.5% of patients experiencing a very good partial response or better (≥VGPR) and 30% a complete response or better (≥CR).
|
|
The median progression-free survival and overall survival were 4.5 months and 15.5 months, respectively. |
|
The most common any grade treatment-emergent adverse events (TEAEs) included neutropenia, infections, and cytokine release syndrome.
|
|
The safety profile of teclistamab was largely comparable in patients with and without prior exposure to anti-BCMA therapy. |
|
The findings from the study demonstrate the clinical benefit of teclistamab as a therapeutic option for patients with RRMM previously treated with BCMA-targeted therapies. |
- Touzeau C, Krishnan A, Moreau P, et al. Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies. Blood. 2024. Online ahead of print. DOI: 1182/blood.2023023616
Your opinion matters
10 votes - 18 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox